1. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

MAPKs

" in MedChemExpress (MCE) Product Catalog:

457

Inhibitors & Agonists

5

Screening Libraries

1

Fluorescent Dye

19

Peptides

160

Natural
Products

6

Isotope-Labeled Compounds

41

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2232

    Akt p38 MAPK Cancer
    N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases the phosphorylation levels of Akt and p38 MAPK .
    N-​Feruloyloctopamine
  • HY-N1914
    Ergothioneine
    5 Publications Verification

    L-(+)-Ergothioneine

    Endogenous Metabolite p38 MAPK Akt Keap1-Nrf2 NF-κB Others
    Ergothioneine is an imidazole-2-thione derivative with orally active histidine betaine. Ergothioneine is a specific inhibitor of p38-MAPK and Akt, which plays a protective role in cell apoptosis induced by stress. Ergothioneine has antioxidant activity .
    Ergothioneine
  • HY-P10072A

    Hsp25 kinase inhibitor acetate; Mk2 pseudosubstrate acetate

    JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK Others
    MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation .
    MK2-IN-5 acetate
  • HY-N8835

    p38 MAPK Neurological Disease
    Cannabisin D inhibits proliferation and migration of glioblastoma cells through MAPKs signaling .
    Cannabisin D
  • HY-146032

    p38 MAPK Neurological Disease Inflammation/Immunology
    p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC50 of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .
    p38-α MAPK-IN-4
  • HY-N8453

    Methyl 3,5-dicaffeoyl quinic acid

    p38 MAPK Neurological Disease
    Macranthoin G is an inhibitor of p38 MAPK. Macranthoin G protects the cytotoxicity induced by Aβ or hydrogen peroxide in neuronal cells by downregulating p38 MAPK. Macranthoin G can used in study Alzheimer’s Disease .
    Macranthoin G
  • HY-N8311

    NF-κB Inflammation/Immunology
    Goshonoside F5 can be isolated from the unripe fruits of Rubus chingii. Goshonoside F5 has anti-inflammatory activity, and inhibits NF-κB and MAPK signaling pathway .
    Goshonoside F5
  • HY-P10072

    Hsp25 kinase inhibitor; Mk2 pseudosubstrate

    ERK JNK p38 MAPK HSP MAPKAPK2 (MK2) Others
    MK2-IN-5 is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation .
    MK2-IN-5
  • HY-10403A

    p38 MAPK Inflammation/Immunology
    (aS)-PH-797804 is a selective p38 MAPK inhibitor with IC50 values for p38 α /β of 26 nM and 102 nM, respectively. (aS)-PH-797804 has anti-inflammatory activity .
    (aS)-PH-797804
  • HY-P10438

    Raf Cancer
    Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by Tat-braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .
    Tat-braftide
  • HY-121087
    BCI-215
    2 Publications Verification

    Phosphatase Cancer
    BCI-215 is a potent and tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells .
    BCI-215
  • HY-108644

    p38 MAPK Inflammation/Immunology
    SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD) .
    SB 706504
  • HY-N1966
    (E)-Osmundacetone
    2 Publications Verification

    p38 MAPK JNK ERK Neurological Disease
    (E)-Osmundacetone is the isomer of Osmundacetone. Osmundacetone significantly suppresses the phosphorylation of MAPKs, including JNK, ERK, and p38 kinases. Osmundacetone has a neuroprotective effect against oxidative stress .
    (E)-Osmundacetone
  • HY-112389
    p38 MAP Kinase Inhibitor III
    1 Publications Verification

    p38 MAPK Inflammation/Immunology
    p38 MAP Kinase Inhibitor III (compound 7h) is a p38 MAPK inhibitor with an 50 of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with 50 values of 0.37 μM and 0.044 μM, respectively .
    p38 MAP Kinase Inhibitor III
  • HY-W015445

    p38 MAPK Metabolic Disease
    SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .
    SD-169
  • HY-N2491

    NF-κB Cancer
    Deoxyelephantopin, a natural bioactive sesquiterpene lactone from Elephantopus scaber, has shown promising anticancer effects against a broad spectrum of cancers. Deoxyelephantopin inhibits NF-κB, MAPK, PI3K/Akt, and β-catenin signaling .
    Deoxyelephantopin
  • HY-162228

    COX Phospholipase Inflammation/Immunology
    VI-60 is a dual, orally active inhibitor of cPLA2 and COX-2, which reveals an anti-inflammtory efficacy through the inhibition of p38 MAPK/cPLA2/COX-2/PGE2 pathway .
    VI-60
  • HY-N4019

    TGF-β Receptor Metabolic Disease
    Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways .
    Maohuoside A
  • HY-W100287

    NF-κB p38 MAPK Neurological Disease Inflammation/Immunology
    Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline A has anti-neuroinflammatory activity .
    Murrayafoline A
  • HY-145026

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 4
  • HY-145027

    ERK Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 5
  • HY-28325

    Reactive Oxygen Species p38 MAPK Cancer
    AMC-04 is an unfolded protein response (UPR) activator, which activates UPR pathway through ROS and p38 MAPK signaling and induces apoptotic cell death. AMC-04 can be used for cancer research .
    AMC-04
  • HY-145025

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
    ERK1/2 inhibitor 3
  • HY-145028

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1) .
    ERK1/2 inhibitor 6
  • HY-N2497
    Isoliquiritin apioside
    1 Publications Verification

    NF-κB MMP p38 MAPK Cancer
    Isoliquiritin apioside significantly decreases PMA-induced increases in MMP9 activities and suppresses PMA-induced activation of MAPK and NF-κB. Isoliquiritin apioside auppresseses invasiveness and angiogenesis of cancer cells and endothelial cells .
    Isoliquiritin apioside
  • HY-145564A

    PF-07265803 hydrochloride

    p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of p38α MAPK. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain .
    Emprumapimod hydrochloride
  • HY-116088

    LPL Receptor Inflammation/Immunology
    W123, a FTY720 analog, is a competitive sphingosine 1-phosphate type 1 (S1P1) receptor antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization .
    W123
  • HY-161513

    COX NO Synthase Inflammation/Immunology
    iNOS/COX-2-IN-1 (Compound 12e) is an inhibitor of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). iNOS/COX-2-IN-1 inhibits the NF-κB and MAPKs signaling pathways and thus exerts anti-inflammatory effects .
    iNOS/COX-2-IN-1
  • HY-W041308

    Kathon 930

    GnRH Receptor Endocrinology
    DCOIT is a representative isothiazolinone that stimulates the gonadotropin-releasing hormone receptor (GnRHR)-mediated synthesis of follicle-stimulating hormone and luteinizing hormone in the brain. DCOIT interferes with G protein-coupled receptors, MAPK and Ca 2+ signaling cascades .
    DCOIT
  • HY-124944

    Ras Cancer
    APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity .
    APS6-45
  • HY-122961

    1,2-Didehydromiltirone

    NF-κB p38 MAPK Inflammation/Immunology
    Dehydromiltirone (1,2-Didehydromiltirone) is a diterpenoid quinone with an anti-inflammatory effect. Dehydromiltirone prevents liver injury by modifying the MAPK and NF-κB signaling pathways, reducing neuroinflammatory responses, and inhibiting platelet aggregation. Dehydromiltirone can be used for osteoporosis research .
    Dehydromiltirone
  • HY-100278

    p38 MAPK Inflammation/Immunology
    AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease .
    AKP-001
  • HY-142452

    Raf Cancer
    Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .
    Pan-RAF kinase inhibitor 1
  • HY-125588
    Chromium picolinate
    1 Publications Verification

    Chromium (III) picolinate; Cr(Pic)3

    Apoptosis p38 MAPK Metabolic Disease
    Chromium picolinate (Chromium (III) picolinate) is a compound that has oral activity. Chromium picolinate induces apoptosis. Chromium picolinate is the activator of p38 MAPK. Chromium picolinate has antioxidant activity. Chromium picolinate can be used in research on type 2 diabetes .
    Chromium picolinate
  • HY-13703

    Apoptosis Cancer
    Nimustine is a nitrosourea alkylating agent. Nimustine induces cell apoptosis, and activates DNA damage response and MAPK signaling. Nimustine shows anti-cancer effects, it can be used for the research of cancer .
    Nimustine
  • HY-137092
    IACS-13909
    3 Publications Verification

    SHP2 Phosphatase Cancer
    IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers .
    IACS-13909
  • HY-116626

    NF-κB p38 MAPK MMP Cancer
    SM-7368 is a potent NF-kB inhibitor that targets downstream of MAPK p38 activation . SM-7368 inhibits TNF-α-induced MMP-9 upregulation. SM-7368 can be used for the research of chemotherapies targeting TNF-α-mediated tumor invasion and metastasis .
    SM-7368
  • HY-N3188

    Akt NF-κB Infection
    Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways .
    Niloticin
  • HY-P10367

    MAPKAPK2 (MK2) Checkpoint Kinase (Chk) AMPK Others
    Ziptide is a substrate for MAPK activated protein kinase 2 (MAPKAPK2, Km = 5 μM), MAPKAPK3 (Km = 30 μM), PARK (Km = 40 μM), checkpoint kinase 1 (Chk1, Km = 5 μM), AMP-activated protein kinase (AMPK, Km = 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, Km = 300 μM) .
    Ziptide
  • HY-114491

    ERK Raf Cancer
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib
  • HY-114491A

    ERK Raf Cancer
    Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib hydrochloride
  • HY-115888

    Macrophage migration inhibitory factor (MIF) Others Cancer
    MIF2-IN-1 (compound 5d) is a potent inhibitor of MIF2 tautomerase with an IC50 of 1.0 μM. MIF2-IN-1 suppresses the proliferation of non-small cell lung cancer cells by the induction of cell cycle arrest via deactivation of the MAPK pathway. MIF2-IN-1 has the potential for the research of cancer diseases .
    MIF2-IN-1
  • HY-N1818

    3-Deoxysappanone B

    p38 MAPK Neurological Disease Inflammation/Immunology
    Deoxysappanone B (3-Deoxysappanone B) is a homoisoflavone compound isolated from Caesalpinia sappan L (Lignum Sappan). Deoxysappanone B has anti-neuroinflammatory and neuroprotective effects and inhibits the production of neuroinflammatory mediators by blocking the IκB kinase (IKK)-NF-κB and p38/ERK MAPK pathways. Deoxysappanone B can be used in disease studies of neuritis and inflammation-related neurological damage .
    Deoxysappanone B
  • HY-B0466
    Cloxacillin sodium monohydrate
    3 Publications Verification

    Beta-lactamase Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
    Cloxacillin sodium monohydrate
  • HY-B0466B
    Cloxacillin sodium
    3 Publications Verification

    Beta-lactamase Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
    Cloxacillin sodium
  • HY-B0466A

    Beta-lactamase Antibiotic Bacterial Infection Inflammation/Immunology Cancer
    Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
    Cloxacillin
  • HY-N8211
    Gypenoside L
    2 Publications Verification

    p38 MAPK ERK NF-κB Inflammation/Immunology Cancer
    Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines. Gypenoside L also can activate p38 and ERK MAPK pathways and NF-κB pathway to induce senescence. Gypenoside L exhibits anti-tumor and anti-inflammatory activities .
    Gypenoside L
  • HY-145564

    PF-07265803

    p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .
    Emprumapimod
  • HY-168090

    p38 MAPK NF-κB RANKL/RANK Endocrinology
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
    Anti-osteoporosis agent-11
  • HY-168012

    Ras Phosphatase Cancer
    Pan-RAS-IN-6 (compound 24) is an inhibitor targeting DUSP6, which reduces MAPK activation in the brain of the NCI-H1373-Luc model (DUSP6), at the same time, it shows significant tumor growth inhibition and tumor regression effects in the NSCLC brain metastasis mouse model. Pan-RAS-IN-6 shows high selectivity and strong inhibitory effects, especially in KRAS mutation-related signaling pathways, demonstrating varying inhibitory activity against different KRAS mutants and interacting proteins. The IC50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively .
    Pan-RAS-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: